Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.71 |
| ▸ | DHODH | Q02127 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | RXRA | P19793 | 5/20 | 0.58 |
| ▸ | RXRB | P28702 | 5/20 | 0.58 |
| ▸ | ERN1 | O75460 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | FABP1 | P07148 | 1/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577419 | 0.90 | KMO (0.87) | KMODHODHLMNAGAARXRA | |
| SCHEMBL14683877 | 0.90 | KMO (0.87) | KMODHODHLMNAGAARXRA | |
| SCHEMBL18621851 | 0.89 | DHODH (0.69) | KMODHODHRXRARXRBALDH1A1 | |
| SCHEMBL3220396 | 0.88 | KMO (0.91) | KMODHODHLMNAGAARXRA | |
| SCHEMBL437537 | 0.88 | KMO (0.91) | KMODHODHLMNAGAARXRA | |
| SCHEMBL121813 | 0.86 | KMO (0.68) | KMODHODHLMNAGAARXRA | |
| SCHEMBL69066 | 0.86 | KMO (0.80) | KMOLMNAGAARXRARXRB | |
| SCHEMBL29904703 | 0.86 | KMO (0.80) | KMOLMNAGAARXRARXRB | |
| SCHEMBL3551496 | 0.86 | KMO (0.80) | KMOLMNAGAARXRARXRB | |
| SCHEMBL10768172 | 0.86 | KMO (0.80) | KMOLMNAGAARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117623975-A | Allyl-containing alpha-quaternary carbon secondary amine compound and oxazine compound synthesized by same and containing quaternary carbon center | 扬州大学 | 2024-03-01 | — | — | CN | claimed |
| US-20100331366-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS ,LLC (US) | 2010-12-30 | — | — | US | claimed |
| EP-2129652-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2008101907-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (GB) | 2008-08-28 | — | — | WO | claimed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20240389450-A1 | LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE | Sharp Display Technology Corporation (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4389263-A1 | SUBSTITUTED TRIANGLAMINE AND USES THEREOF | Centre national de la recherche scientifique (FR) | 2024-06-26 | — | — | EP | disclosed |
| CN-117981493-A | Light-emitting element, method for manufacturing light-emitting element, display device, and method for manufacturing display device | 夏普显示科技株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-117623975-A | Allyl-containing alpha-quaternary carbon secondary amine compound and oxazine compound synthesized by same and containing quaternary carbon center | 扬州大学 | 2024-03-01 | — | — | CN | disclosed |
| US-11787824-B2 | Titanium heterometallic metal-organic solids, method for obtaining them and their uses | UNIVERSITAT DE VALÈNCIA (ES) | 2023-10-17 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-5583141-A | ADMINISTERING AS THERAPEUTIC AGENTS OF CIRCULATORY DISEASES; AZILSARTAN; ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| US-5545645-A | Heterocyclic derivatives in the treatment of ischaemia and related diseases | SYNTEX PHARMACEUTICALS, LIMITED (GB) | 1996-08-13 | — | — | US | disclosed |
| EP-0693062-A1 | HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES | SYNTEX PHARMACEUTICALS LTD. (GB) | 1996-01-24 | — | — | EP | disclosed |
| US-5428037-A | Piperazine derivatives; calcium and sodium channel antagonists | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1995-06-27 | — | — | US | disclosed |
| WO-1994024116-A1 | HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES | SYNTEX PHARMACEUTICALS LIMITED (GB) | 1994-10-27 | — | — | WO | disclosed |
| US-5354766-A | 2-Ethoxy-1-((2'(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl)methyl)benzimidazole-7-carboxylic acid; hypotensive agents; CNS activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| US-5243054-A | Hypotensive agents, cardiovascular disorders or nervous system disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0520423-A2 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | KMO 1668/4885DHODH 1813/4885LMNA 991/4885 |
| US-11787824-B2 | Titanium heterometallic metal-organic solids, method for obtaining them and their uses | FTO, TDO2, PICALM | KMO 276/4885DHODH 1141/4885LMNA 3973/4885 |
| US-20100331366-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | KMO 2539/4885DHODH 82/4885LMNA 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.